RxDoctor Payments Data

Lakshminarayan Yerra, MD

Interventional Cardiology · Wilkes Barre, PANPI 1366549933

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 114 payments — averaging $12.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$517
  • Pfizer$141
  • Johnson & Johnson$129
  • Amgen$125
  • Scpharmaceuticals Inc.$51
  • Novo Nordisk$45
  • plus $401 from 15 others

What the payments were for

  • Food & beverage$1,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,408 in reported general payments places this provider in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$218,877
Medicare patients
1,809
Services billed
4,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$230,146
EntrestoSacubitril/Valsartan79$120,900
XareltoRivaroxaban68$85,065
FarxigaDapagliflozin Propanediol80$68,151
Repatha SureclickEvolocumab56$55,053
JardianceEmpagliflozin40$42,793
Praluent PenAlirocumab42$26,492
VascepaIcosapent Ethyl45$25,610
NexlizetBempedoic Acid/Ezetimibe22$17,770
Ranolazine ErRanolazine75$7,669
Metoprolol Succinate554$7,228
Ezetimibe139$4,613
Atorvastatin Calcium318$2,371
Droxidopa12$2,362
Potassium Chloride139$1,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$230,146224 claims
NovartisEntresto$517$120,90079 claims
Johnson & JohnsonXarelto$129$85,06568 claims
AstraZenecaFarxiga$24$68,15180 claims
Boehringer IngelheimJardiance$29$42,79340 claims
Esperion Therapeutics, Inc.Nexlizet$45$17,77022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Wilkes Barre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →